Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bio-Path Holdings, Inc. (BPTH : OTC)

• Company Description    BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $0.16 Daily Weekly Monthly 20 Day Moving Average: 43,320 shares Shares Outstanding: 8.31 (millions) Market Capitalization: $1.35 (millions) Beta: -0.03 52 Week High: $0.23 52 Week Low: $0.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.09% -28.86% 12 Week -1.45% -17.11% Year To Date -85.98% -86.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4710 BELLAIRE BOULEVARD SUITE 210 - BELLAIRE,TX 77401 USA ph: 832-742-1357 fax: - will@sternir.com http://www.biopathholdings.com

• General Corporate Information    Officers Peter H. Nielsen - President Chief Executive Officer Chief Financial Heath W. Cleaver - Director Paul D. Aubert - Director Aline B. Sherwood - Director Douglas P. Morris - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 09057N409 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/21/25 Share - Related Items Shares Outstanding: 8.31 Most Recent Split Date: 2.00 (0.05:1) Beta: -0.03 Market Capitalization: $1.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.50 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/21/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 91.80% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -285.40 12/31/24 - -303.16 Current Ratio 06/30/25 - - 03/31/25 - 0.45 12/31/24 - 1.15 Quick Ratio 06/30/25 - - 03/31/25 - 0.45 12/31/24 - 1.15 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -0.31 12/31/24 - 0.03 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©